TuftsCSDD-Logo-Color.jpg
Effective Drug Development Outsourcing Requires a Plan, According to Tufts Center for the Study of Drug Development
02 avr. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 2, 2008) - While the trend to outsource key elements of drug development to service providers could slow down due in part to rising operating costs worldwide, drug...
TuftsCSDD-Logo-Color.jpg
Number of Monoclonal Antibody Products in Development Nearly Tripled in Last Decade, According to Tufts Center for the Study of Drug Development
11 mars 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 11, 2008) - The number of monoclonal antibody products -- known as mAbs -- entering clinical study nearly tripled in the last decade and now require 7.6 years on...
NineSigma Capitalizes on Growth of Open Innovation; Reports a Record Year for 2007
21 févr. 2008 09h33 HE | NineSigma, Inc.
CLEVELAND, OH--(Marketwire - February 21, 2008) - As a result of the growing demand for open innovation solutions, NineSigma today reported record revenues for 2007. The company's success was...
TuftsCSDD-Logo-Color.jpg
Pharmaceutical and Biopharmaceutical Companies Need to Reassess the Way They Operate, According to Tufts Center for the Study of Drug Development
05 févr. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - February 5, 2008) - How drug developers organize their companies affects operational and financial performance, according to new research findings presented to a panel of...
TuftsCSDD-Logo-Color.jpg
Tufts Center for the Study of Drug Development to Launch R&D Senior Management Roundtable Series Feb. 28
28 janv. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 28, 2008) - The Tufts Center for the Study of Drug Development today announced that it is expanding its R&D Senior Management Roundtable, from a single...
TuftsCSDD-Logo-Color.jpg
Growing Complexity of Clinical Trials Increases Burden on Investigators and Volunteers, According to Tufts Center for the Study of Drug Development
15 janv. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 15, 2008) - More complex clinical trial protocols are demanding more of investigative site personnel and study volunteers, leading to longer clinical trials and...
TuftsCSDD-Logo-Color.jpg
New Approaches to Drug Development Will Drive Drug Company Success, According to Tufts Center for the Study of Drug Development
03 janv. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 3, 2008) - Drug companies, under significant pressure to develop new prescription medicines faster and at lower cost, are more likely to succeed if they change the...
TuftsCSDD-Logo-Color.jpg
Notable Gender, Racial Disparities Exist Among U.S. Clinical Investigators, According to the Tufts Center for the Study of Drug Development
13 nov. 2007 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 13, 2007) - Although the overwhelming majority of physicians in the United States have high interest in participating in clinical research studies, the actual...
TuftsCSDD-Logo-Color.jpg
Despite More Cancer Drugs in R&D, Overall U.S. Approval Rate Is Eight Percent, According to the Tufts Center for the Study of Drug Development
05 sept. 2007 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 5, 2007) - Although the number of new cancer drugs entering clinical development more than doubled between the early 1990s and mid-2000s, only eight percent of...
TuftsCSDD-Logo-Color.jpg
Follow-on Drugs Are Key to World Health Organization, According to the Tufts Center for the Study of Drug Development
10 juil. 2007 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 10, 2007) - Follow-on drugs play a central role in World Health Organization (WHO) drug policy, suggesting that initiatives which impede follow-on drug research and...